IONIQ is “Clinical Diagnostics Solution of the Year 2022”

For IONIQ Sciences, 2022 was another big year. As we respond to the FDA’s substantive review of our De Novo application for the ‘breakthrough‘ IONIQ ProLung Test, powerful macroeconomic factors are highlighting the importance of early cancer detection. Despite uncertain conditions in the financial market, we have a compelling message for potential institutional and strategic investors at […]

IONIQ Receives Three Awards including ‘Best Medical Technology Company 2022’